Abstract
We have identified four new μ-opiod receptor (MOR)-1 exons, indicating that the gene now contains at least nine exons spanning more than 200 kilobases. Replacement of exon 4 by combinations of the new exons yields three new receptors. When expressed in Chinese hamster ovary cells, all three variants displayed high affinity for μ-opioid ligands, but κ and δ drugs were inactive. However, there were subtle, but significant, differences in the binding profiles of the three variants among themselves and from MOR-1. Immunohistochemically, the major variant, MOR-1C, displayed a regional distribution quite distinct from that of MOR-1. Region-specific processing also was seen at the mRNA level. Antisense mapping revealed that the four new exons were all involved in morphine analgesia. Together with two other variants generated from alternative splicing of exon 4, there are now six distinct MOR-1 receptors.
Footnotes
- Received February 3, 1999.
- Accepted April 13, 1999.
-
Send reprint requests to: Dr. Gavril W. Pasternak, Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021. E-mail:pasterng{at}mskmail.mskcc.org
-
This work was supported in part by the National Institute on Drug Abuse Grants DA02615, DA06241, and DA07242; Senior Scientist Award DA00220 (to G.W.P.) and Research Scientist Development Award DA00296 (to Y.-X.P.); and Core Grant CA08748 (to the Memorial Sloan-Kettering Cancer Center).
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|